<DOC>
	<DOCNO>NCT01333007</DOCNO>
	<brief_summary>This observational study evaluate modality , efficacy safety Avastin ( bevacizumab ) first-line treatment combination chemotherapy patient inoperable advanced , metastatic recurrent non-squamous non-small cell lung cancer clinical practice . Data collect patient 18 month initiation Avastin therapy .</brief_summary>
	<brief_title>An Observational Study Avastin ( Bevacizumab ) Combination With Chemotherapy Patients With Metastatic Recurrent Non-Squamous Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Inoperable advance , metastatic recurrent nonsquamous nonsmall cell lung cancer ( NSCLC ) Treating physician 's decision initiate firstline Avastin treatment Participation clinical trial evaluate anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>